RAPP

+ Watchlist + Portfolio

Rapport Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $32.83
52-Week Range: $23.75 – $52.93
Market Cap: $1.54B
P/E (TTM): —
EPS (TTM): -3.03
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.65
PEG Ratio: —
Return on Equity: -39.96%
Return on Assets: -25.78%
Gross Margin: -109.39%
Operating Margin: -767.58%
Profit Margin: 0.00%
Current Ratio: 15.72
Debt/Equity: 0.02
Total Debt: $10.11M
Free Cash Flow: $-56.02M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.12B

RAPP Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Research & Development	$28.00M	$60.94M	$94.79M
Selling, General & Admin	$8.18M	$22.12M	$30.31M
Operating Expenses	$36.18M	$83.06M	$125.10M
Operating Income	-$36.18M	-$83.06M	-$125.10M
EBITDA	-$36.07M	-$82.22M	-$124.08M
Pretax Income	-$34.78M	-$78.31M	-$111.48M
Income Tax	$10.00K	$0.00	—
Net Income	-$34.79M	-$78.31M	-$111.48M
Diluted EPS	-23.10	-3.78	-2.86
Diluted Shares	1.51M	20.74M	38.93M

RAPP Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.18M	-$64.83M	-$87.47M
Capital Expenditure	-$1.64M	-$2.40M	-$616.00K
Free Cash Flow	-$28.82M	-$67.23M	-$88.09M
Depreciation & Amortisation	$112.00K	$839.00K	$1.02M
Stock-Based Compensation	$3.52M	$10.23M	$18.86M
Investing Cash Flow	-$78.86M	-$170.14M	-$187.47M
Financing Cash Flow	$145.14M	$221.63M	$270.79M
Share Repurchases	-$4.00K	$0.00	-$1.00K
Net Change in Cash	$39.09M	-$13.34M	-$4.16M

RAPP Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$20.00M	$0.00
Research & Development	$22.68M	$22.28M	$30.26M	$32.72M	$51.41M
Selling, General & Admin	$6.82M	$7.71M	$8.25M	$11.50M	$9.39M
Operating Expenses	$29.50M	$29.99M	$38.51M	$44.22M	$60.81M
Operating Income	-$29.50M	-$29.99M	-$38.51M	-$24.21M	-$60.81M
EBITDA	-$29.24M	-$29.73M	-$38.24M	-$23.99M	-$60.59M
Pretax Income	-$26.73M	-$26.93M	-$33.76M	-$19.86M	-$56.62M
Net Income	-$26.73M	-$26.93M	-$33.76M	-$19.86M	-$56.62M
Diluted EPS	-0.75	-0.71	-0.72	-0.42	-1.19
Diluted Shares	35.44M	37.93M	46.98M	47.24M	47.47M

RAPP Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$55.07M	$251.36M	$52.65M	$78.06M	$63.61M
Receivables	—	—	—	$58.00K	$293.00K
Current Assets	$270.24M	$520.66M	$498.56M	$484.69M	$446.86M
Total Assets	$285.50M	$535.32M	$512.43M	$497.60M	$458.98M
Current Liabilities	$11.88M	$14.32M	$19.05M	$17.90M	$28.42M
Total Debt	$11.86M	$11.87M	$11.48M	$10.80M	$10.11M
Total Liabilities	$21.98M	$23.71M	$27.78M	$26.09M	$36.06M
Retained Earnings	-$174.54M	-$201.47M	-$235.23M	-$255.09M	-$311.70M
Shareholders' Equity	$263.51M	$511.62M	$484.65M	$471.51M	$422.93M
Working Capital	$258.36M	$506.34M	$479.51M	$466.80M	$418.43M

RAPP Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$25.07M	-$17.46M	-$24.70M	-$13.06M	-$41.45M
Capital Expenditure	-$22.00K	-$134.00K	-$169.00K	-$86.00K	-$78.00K
Free Cash Flow	-$25.09M	-$17.60M	-$24.87M	-$13.15M	-$41.53M
Depreciation & Amortisation	$252.00K	$256.00K	$265.00K	$227.00K	$212.00K
Stock-Based Compensation	$4.39M	$4.74M	$5.69M	$6.96M	$7.20M
Investing Cash Flow	$22.60M	-$56.78M	-$174.32M	$37.94M	$25.60M
Financing Cash Flow	-$63.00K	$270.53M	$311.00K	$531.00K	$1.41M
Share Repurchases	$0.00	$0.00	$0.00	-$5.00K	$0.00
Net Change in Cash	-$2.54M	$196.29M	-$198.71M	$25.41M	-$14.44M

Market Snapshot

About

Rapport Therapeutics, Inc. is a precision neuroscience company developing small molecule medicines for central nervous system disorders, focusing on genetically defined patient populations with high unmet needs.